“Wegovy and Ozempic are both GLP-1 receptor agonists and share the same active ingredient, semaglutide, but they are used for different purposes and have different dosages,” said Hill.
Wegovy is specifically meant to be used for weight loss in people who have clinical obesity, defined as having a body mass index (BMI) of 30 or greater. It’s also meant for people who are clinically overweight — a BMI of 27 or greater — in addition to having other related health conditions such as diabetes or heart disease.
Ozempic, on the other hand, is meant to be used as a treatment for type 2 diabetes, though weight loss can still be one of its side effects.
“The recommended dose for Wegovy is 2.4 mg once weekly while Ozempic is either 0.5 mg or 1 mg once weekly,” explained Hill.